Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Briacell Therapeutics Corp T.BCT

Alternate Symbol(s):  BCTX | BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.


TSX:BCT - Post by User

Bullboard Posts
Post by ChupacabraBuenoon Apr 03, 2019 2:48pm
88 Views
Post# 29577731

Buy the rumor, sell the (good?) news.

Buy the rumor, sell the (good?) news.

BriaCell's Lead Candidate Combined With KEYTRUDA(R): Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity


The headline is clearly positive. The text seems more mixed. But these patients had already proven difficult to treat:

-- All 6 patients were very heavily pre-treated with a median of 5 prior 
systemic therapy regimens (such as chemotherapy) prior to enrollment in 
BriaCell's Combination Study. 

-- These patients previously did not respond to a number of currently 
available therapies outside of BriaCell, and most had very weak immune 
systems, further emphasizing the importance of the positive results 
observed in BriaCell's Combination Study. 



Bullboard Posts